Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.

European journal of cancer (Oxford, England : 1990) - 1 Dec 2023

Helal Clara, Pobel Cédric, Bayle Arnaud, Vasseur Damien, Nicotra Claudio, Blanc-Durand Félix, Naoun Natacha, Bernard-Tessier Alice, Patrikidou Anna, Colomba Emeline, Flippot Ronan, Fuerea Alina, Auger Nathalie, Ngo Camus Maud, Besse Benjamin, Lacroix Ludovic, Rouleau Etienne, Ponce Santiago, Italiano Antoine, Loriot Yohann

Abstract excerpt

BACKGROUND: Genomic stratification may help improve the management of patients with metastatic urothelial cancer (mUC), given the recent identification of targetable alterations. However, the collection of tissue samples remains challenging. Here, we assessed the clinical utility of plasma circulating tumour DNA (ctDNA) sequencing in these patients. METHODS: Patients with mUC were prospectively enroled in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 37897866
DOI: 10.1016/j.ejca.2023.113368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.PMID 37897866Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.Semantic proximity Read ↗

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.Semantic proximity Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Semantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.Semantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.Semantic proximity Read ↗

Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.Semantic proximity Read ↗

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.Semantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.